California is currently home to 5955 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Los Angeles, San Francisco, San Diego and Sacramento. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells
Recruiting
This phase I trial tests the safety, side effects, and best dose of E-SYNC chimeric antigen receptor (CAR) T cells after lymphodepleting chemotherapy in treating patients with EGFRvIII positive (+) glioblastoma. Chimeric antigen receptor (CAR) T-cell therapy is a type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so the CAR T cells will attack cancer cells. T cells are taken from a patient's blood. Then the gene for a special receptor that... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/16/2024
Locations: University of California, San Francisco, San Francisco, California
Conditions: EGFR Gene Mutation, Glioblastoma, MGMT-Unmethylated Glioblastoma, Recurrent Glioblastoma
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza.
Recruiting
The purpose of this study is to understand the safety and effects of a combined influenza and COVID-19 vaccine. This combined vaccine is compared to separate vaccines for the protection against influenza and SARS-CoV-2. Influenza and COVID-19 are diseases that can spread easily from one person to another and cause body aches, fever, cough, and other symptoms. Giving both influenza and COVID-19 vaccines together against influenza and SARS-CoV-2 could provide great benefits to both patients and ca... Read More
Gender:
All
Ages:
Between 18 years and 64 years
Trial Updated:
04/16/2024
Locations: Velocity Clinical Research, Banning, Banning, California
Conditions: Influenza, COVID-19
A Study of Efficacy and Safety of Rosnilimab in Subjects With Moderate to Severe Ulcerative Colitis (ROSETTA)
Recruiting
ROSETTA STUDY: This study will evaluate the safety, tolerability, and efficacy of Rosnilimab in subjects with moderate to severe ulcerative colitis (UC)
Gender:
All
Ages:
18 years and above
Trial Updated:
04/16/2024
Locations: AnaptysBio Investigative Site 10-117, Garden Grove, California
Conditions: Ulcerative Colitis
Study Evaluating Safety and Efficacy of Ropanicant in MDD Patients
Recruiting
This is an open-label, parallel-group study to evaluate the safety and efficacy of ropanicant in participants with moderate to severe Major Depressive Disorder (MDD).
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
04/16/2024
Locations: Clinical Innovations, Inc, Bellflower, California
Conditions: Major Depressive Disorder
StrokeCog-BBB to Study Cognitive Outcomes Following Stroke
Recruiting
The goal of this observational study is to learn about cognitive outcomes in stroke patients. The main question it aims to answer are: 1. Is blood-brain barrier permeability compromised for years after stroke, 2. Is a blood biomarker of imbalanced angiogenesis dysregulated in chronic stroke and 3. Are there biomarkers that separately or together predicts cognitive decline after stroke, and are other MRI, blood, and clinical characteristics that are associated. Participants will undergo cognitive... Read More
Gender:
All
Ages:
Between 45 years and 90 years
Trial Updated:
04/16/2024
Locations: Stanford University Hospital, Palo Alto, California
Conditions: Stroke
Study of DF6215 in Patients With Advanced Solid Tumors
Recruiting
DF6215-001 is a study of a modified human cytokine (interleukin-2; IL-2) that retains the ability to bind to a certain part of the IL-2 receptor on a subset of white blood cells (lymphocytes), which can help recognize and kill tumor cells. The study will occur in two phases. The first phase will be a dose escalation phase, enrolling patients with various types of solid tumors. The second phase, Phase 1b, will include a dose expansion using the best dose selected from the first phase of the study... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/16/2024
Locations: Sarcoma Oncology Center, Santa Monica, California
Conditions: Solid Tumor, Adult
Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects With Chronic Spontaneous Urticaria
Recruiting
Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects with Chronic Spontaneous Urticaria
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
04/16/2024
Locations: First OC Dermatology Research, Inc., Fountain Valley, California
Conditions: Chronic Spontaneous Urticaria
A Study of onCARlytics (CF33-CD19) in Combination With Blinatumomab in Adults With Advanced or Metastatic Solid Tumors (OASIS)
Recruiting
This is an open-label, dose escalation and dose expansion, multi-center phase I study evaluating the safety and tolerability of CF33-CD19 administered intravenously (IV) or intratumorally (IT) in combination with blinatumomab in adults with advanced or metastatic solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/16/2024
Locations: City of Hope, Duarte, California
Conditions: Solid Tumor, Adult
Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
Recruiting
This phase II trial studies the side effects of acalabrutinib, obinutuzumab, and glofitamab and how well they work together for treating patients with mantle cell lymphoma that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). Acalabrutinib is in a class of medications called kinase inhibitors. It blocks a protein called BTK, which is present on B-cell (a type of white blood cells) cancers such as mantel cell lymphoma at abnormal... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/16/2024
Locations: City of Hope Medical Center, Duarte, California
Conditions: Mantle Cell Lymphoma
A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations
Recruiting
The primary objective of the study is to demonstrate the efficacy of high dose and low dose fluticasone propionate (Fp)/albuterol sulfate (ABS) integrated electronic module multidose dry powder inhaler (eMDPI) compared to ABS eMDPI in decreasing severe clinical asthma exacerbation (CAEs). Secondary Objectives: To evaluate the efficacy of Fp/ABS compared to ABS and the effect on systemic corticosteroid (SCS) exposure To evaluate the safety and tolerability of Fp/A BS The duration for each part... Read More
Gender:
All
Ages:
4 years and above
Trial Updated:
04/16/2024
Locations: Teva Investigational Site 15629, Banning, California
Conditions: Asthma
A Study Following Women in Menopause Treated With a Non-hormonal Therapy for Hot Flashes and Night Sweats
Recruiting
Hot flashes and night sweats (also known as vasomotor symptoms or VMS) are the most common symptoms which bother women in menopause. This study will follow women going through menopause who have hot flashes and night sweats that cause them bother. They will be starting a non-hormonal therapy prescribed by their healthcare provider (HCP) to treat these symptoms. The women will visit their HCP's office, research center, or both. They will receive prescriptions for the non-hormonal therapy from the... Read More
Gender:
Female
Ages:
Between 40 years and 75 years
Trial Updated:
04/16/2024
Locations: Torrance Clinical Research Institute,Inc, Lomita, California
Conditions: Hot Flashes
A Study to Evaluate Long-term Safety of Ecopipam Tablets in Children, Adolescents and Adults With Tourette's Disorder
Recruiting
The primary objective of this study is to evaluate the long-term safety and tolerability of ecopipam tablets in children (greater than or equal to [>=] 6 and less than [<] 12 years of age), adolescents (>=12 and <18 years of age), and adults (>=18 years of age) with Tourette's Syndrome (TS).
Gender:
All
Ages:
6 years and above
Trial Updated:
04/16/2024
Locations: Advanced Research Center, Anaheim, California
Conditions: Tourette Syndrome